Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

European Heart Journal Cardiovascular Imaging

Volumn 15, Issue 10, 2014, Pages 1063-1093

  Plana, Juan Carlos ^a   Galderisi, Maurizio ^b   Barac, Ana ^c   Ewer, Michael S ^d   Ky, Bonnie ^e   Scherrer Crosbie, Marielle ^f   Ganame, Javier ^g   Sebag, Igal A ^h   Agler, Deborah A ^a   Badano, Luigi P ⁱ   Banchs, Jose ^d   Cardinale, Daniela ^j   Carver, Joseph ^k   Cerqueira, Manuel ^a   DeCara, Jeanne M ^l   Edvardsen, Thor ^m   Flamm, Scott D ^a   Force, Thomas ⁿ   Griffin, Brian P ^a   Jerusalem, Guy ^o   Liu, Jennifer E ^p   Magalhães, Andreia ^q   Marwick, Thomas ^r   Sanchez, Liza Y ^d   Sicari, Rosa ^s   Villarraga, Hector R ^t   Lancellotti, Patrizio ^o   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ TEMPLE UNIVERSITY   (United States)

^o UNIVERSITY OF LIÈGE   (Belgium)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q Santa Marie University Hospital   (Portugal)

^r UNIVERSITY OF TASMANIA   (Australia)

^s INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^t MAYO CLINIC   (United States)

more..

Author keywords

Biomarkers; Chemotherapy; Doxorubicin; Early detection; Left ventricular dysfunction; Strain; Three dimensional echocardiography; Trastuzumab

Indexed keywords

BIOLOGICAL MARKER; TROPONIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER PATIENT; CANCER THERAPY; CARDIAC GATED IMAGING; CARDIAC IMAGING; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DEATH; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; DISEASE PREDISPOSITION; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; M MODE ECHOCARDIOGRAPHY; MULTIMODAL IMAGING; MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STRESS ECHOCARDIOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; ADULT; CARDIOLOGY; CHEMICALLY INDUCED; CONSENSUS; FEMALE; HEART DISEASES; MALE; MEDICAL SOCIETY; NEOPLASMS; ONCOLOGY; PRACTICE GUIDELINE; STANDARDS; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARDIOLOGY; CONSENSUS; FEMALE; HEART DISEASES; HUMANS; MALE; MEDICAL ONCOLOGY; MULTIMODAL IMAGING; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84921772410     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jeu192     Document Type: Article

References (238)

1. Tan C., Tasaka H., Yu K.P., Murphy M.L., Karnofsky D.A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia, Cancer 20 (1967) 333-353.
2. Alexander J., Dainiak N., Berger H.J., Goldman L., Johnstone D., Reduto L. et al., Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography, N Engl J Med 300 (1979) 278-283.
3. Lenzhofer R., Dudczak R., Gumhold G., Graninger W., Moser K., Spitzy K.H., Noninvasive methods for the early detection of doxorubicin-induced cardiomyopathy, J Cancer Res Clin Oncol 106 (1983) 136-142.
4. Ramos A., Meyer R.A., Korfhagen J., Wong K.Y., Kaplan S., Echocardiographic evaluation of adriamycin cardiotoxicity in children, Cancer Treat Rep 60 (1976) 1281-1284.
5. Ewer M.S., Ali M.K., Mackay B., Wallace S., Valdivieso M., Legha S.S. et al., A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin, J Clin Oncol 2 (1984) 112-117.
6. Neilan T.G., Jassal D.S., Perez-Sanz T.M., Raher M.J., Pradhan A.D., Buys E.S. et al., Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury, Eur Heart J 27 (2006) 1868-1875.
7. Khouri M.G., Douglas P.S., Mackey J.R., Martin M., Scott J.M., Scherrer-Crosbie M. et al., Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues, Circulation 126 (2012) 2749-2763.
8. Zhang S., LiuX., Bawa-KhalfeT., Lu L.S., Lyu Y.L., Liu L.F. et al., Identification of themolecular basis of doxorubicin-induced cardiotoxicity, NatMed 18 (2012) 1639-1642.
9. Friedman M.A., Bozdech M.J., Billingham M.E., Rider A.K., Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals, JAMA 240 (1978) 1603-1606.
10. Ewer M.S., Lippman S.M., Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity, J Clin Oncol 23 (2005) 2900-2902.
11. Felker G.M., Thompson R.E., Hare J.M., Hruban R.H., Clemetson D.E., Howard D.L. et al., Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy, N Engl J Med 342 (2000) 1077-1084.
12. Lal H., Kolaja K.L., Force T., Cancer genetics and the cardiotoxicity of the therapeutics, J Am Coll Cardiol 61 (2013) 267-274.
13. Ewer M., Suter D., Lenihan D.J., Niculescu L., Breazna A., Motzer R.J. et al., Sunitinib-related hypertension is a randomized placebo-controlled trial of GIST patients, J Clin Oncol 28, 2010. abstract 10059-abstract 10059.
14. Ewer M.S., Perez E.A., Baselga J., Bell R., Brutsaert D., Marty M. et al., P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptinw) in HER2-positive early breast cancer, The Breast 16 (2007) S63.
15. Daher I.N., Kim C., Saleh R.R., Plana J.C., Yusuf S.W., Banchs J., Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients, Echocardiography 28 (2011) 1061-1067.
16. Cheitlin M.D., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davis J.L. et al., ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography), J Am Soc Echocardiogr 16 (2003) 1091-1110.
17. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, et al., ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians, J Am Soc Echocardiogr 24 (2011) 229-267.
18. Steingart R.M., Bakris G.L., Chen H.X., Chen M.H., Force T., Ivy S.P. et al., Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors, Am Heart J 163 (2012) 156-163.
19. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D. et al., Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail 13 (2011) 1-10.
20. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A. et al., Recommendations for chamber quantification: a report from theAmerican Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology, J Am Soc Echocardiogr 18 (2005) 1440-1463.
21. Isner J.M., Ferrans V.J., Cohen S.R., Witkind B.G., Virmani R., Gottdiener J.S. et al., Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy, Am J Cardiol 51 (1983) 1167-1174.
22. Muraru D., Badano L.P., Peluso D., Dal Bianco L., Casablanca S., Kocabay G. et al., Comprehensive analysis of left ventricular geometry and function by threedimensional echocardiography in healthy adults, J Am Soc Echocardiogr 26 (2013) 618-628.
23. Rietzschel E.R., De Buyzere M.L., Bekaert S., Segers P., De Bacquer D., Cooman L. et al., Rationale, design, methods and baseline characteristics of the Asklepios Study, Eur J Cardiovasc Prev Rehabil 14 (2007) 179-191.
24. KuznetsovaT., Herbots L., Lopez B., Jin Y., RichartT., Thijs L. et al., Prevalence of left ventricular diastolic dysfunction in a general population, Circ Heart Fail 2 (2009) 105-112.
25. Friedman G.D., Cutter G.R., Donahue R.P., Hughes G.H., Hulley S.B., Jacobs D.R. Jr. et al., CARDIA: study design, recruitment, and some characteristics of the examined subjects, J Clin Epidemiol 41 (1988) 1105-1116.
26. Lancellotti P., Badano L.P., Lang R.M., Akhaladze N., Athanassopoulos G.D., Barone D. et al., Normal Reference Ranges for Echocardiography: rationale, study design, and methodology (NORRE Study), Eur Heart J Cardiovasc Imaging 14 (2013) 303-308.
27. Bountioukos M., Doorduijn J.K., Roelandt J.R., Vourvouri E.C., Bax J.J., Schinkel A.F. et al., Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity, Eur J Echocardiogr 4 (2003) 300-305.
28. Ryberg M., Nielsen D., Skovsgaard T., Hansen J., Jensen B.V., Dombernowsky P., Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer, J Clin Oncol 16 (1998) 3502-3508.
29. Nielsen D., Jensen J.B., Dombernowsky P., Munck O., Fogh J., Brynjolf I. et al., Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer, J Clin Oncol 8 (1990) 1806-1810.
30. Swain S.M., Whaley F.S., Ewer M.S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer 97 (2003) 2869-2879.
31. Mitani I., Jain D., Joska T.M., Burtness B., Zaret B.L., Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era, J Nucl Cardiol 10 (2003) 132-139.
32. Nousiainen T., Jantunen E., Vanninen E., Hartikainen J., Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients, Br J Cancer 86 (2002) 1697-1700.
33. Schwartz R.G., McKenzie W.B., Alexander J., Sager P., D'Souza A., Manatunga A. et al., Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography, Am J Med 82 (1987) 1109-1118.
34. Jensen B.V., Skovsgaard T., Nielsen S.L., Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients, Ann Oncol 13 (2002) 699-709.
35. Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., Murphy M.L., Cardiac toxicity 4 to 20 years after completing anthracycline therapy, JAMA 266 (1991) 1672-1677.
36. Moja L., Tagliabue L., Balduzzi S., Parmelli E., Pistotti V., Guarneri V. et al., Trastuzumab containing regimens for early breast cancer, Cochrane Database Syst Rev 4 (2012) CD006243.
37. Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M. et al., Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol 20 (2002) 1215-1221.
38. Youssef G., Links M., The prevention and management of cardiovascular complications of chemotherapy in patients with cancer, Am J Cardiovasc Drugs 5 (2005) 233-243.
39. Keefe D.L., Trastuzumab-associated cardiotoxicity, Cancer 95 (2002) 1592-1600.
40. Schuchter L.M., Hensley M.L., Meropol N.J., Winer E.P., American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology, J Clin Oncol 20 (2002) 2895-2903.
41. Carver J.R., Shapiro C.L., Ng A., Jacobs L., Schwartz C., Virgo K.S. et al., American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects, J Clin Oncol 25 (2007) 3991-4008.
42. Jacobs L.D., Salgo I.S., Goonewardena S.,Weinert L., Coon P., Bardo D. et al., Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data, Eur Heart J 27 (2006) 460-468.
43. Otterstad J.E., Froeland G., St John Sutton M., Holme I., Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function, Eur Heart J 18 (1997) 507-513.
44. Thavendiranathan P., Grant A.D., Negishi T., Plana J.C., Popovic Z.B., Marwick T.H., Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy, J Am Coll Cardiol 61 (2013) 77-84.
45. Ewer M.S., Ewer S.M., Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data, J Clin Oncol 27 (2009) 6073-6075.
46. Karakurt C., Kocak G., Ozgen U., Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy, Echocardiography 25 (2008) 880-887.
47. Ganame J., Claus P., Eyskens B., Uyttebroeck A., Renard M., D'hooge J. et al., Acute cardiac functional and morphological changes after Anthracycline infusions in children, Am J Cardiol 99 (2007) 974-977.
48. Tassan-Mangina S., Codorean D., Metivier M., Costa B., Himberlin C., Jouannaud C. et al., Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study, Eur J Echocardiogr 7 (2006) 141-146.
49. Kapusta L., Thijssen J.M., Groot-Loonen J., Antonius T., Mulder J., Daniels O., Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines, Ultrasound Med Biol 26 (2000) 1099-1108.
50. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A. et al., Recommendations for the evaluation of left ventricular diastolic function by echocardiography, Eur J Echocardiogr 10 (2009) 165-193.
51. Mason J.W., Bristow M.R., Billingham M.E., Daniels J.R., Invasive and non-invasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histiopathologic assessment using endomyocardial biopsy, Cancer Treat Rep 62 (1978) 857-864.
52. Tanindi A., Demirci U., Tacoy G., Buyukberber S., Alsancak Y., Coskun U. et al., Assessment of right ventricular functions during cancer chemotherapy, Eur J Echocardiogr 12 (2011) 834-840.
53. Rudski L.G., LaiW.W., Afilalo J., Hua L., Handschumacher M.D., Chandrasekaran K. et al., Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, J Am Soc Echocardiogr 23 (2010) 685-713. quiz 786-8.
54. Montani D., Bergot E., Gunther S., Savale L., Bergeron A., Bourdin A. et al., Pulmonary arterial hypertension in patients treated by dasatinib, Circulation 125 (2012) 2128-2137.
55. Bansal R.C., Infective endocarditis, Med Clin North Am 79 (1995) 1205-1240.
56. RobertsW.C., The congenitally bicuspid aortic valve. A study of 85 autopsy cases, Am J Cardiol 26 (1970) 72-83.
57. Freed L.A., Levy D., Levine R.A., Larson M.G., Evans J.C., Fuller D.L. et al., Prevalence and clinical outcome of mitral-valve prolapse, N Engl J Med 341 (1999) 1-7.
58. Lancellotti P., Nkomo V.T., Badano L.P., Bergler J., Bogaert J., Davin L. et al., Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography, Eur Heart J Cardiovasc Imaging 14 (2013) 721-740.
59. Edoute Y., Haim N., Rinkevich D., Brenner B., Reisner S.A., Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients, Am J Med 102 (1997) 252-258.
60. Eiken P.W., Edwards W.D., Tazelaar H.D., McBane R.D., Zehr K.J., Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985-2000, Mayo Clin Proc 76 (2001) 1204-1212.
61. Hamza A., Tunick P.A., Kronzon I., Echocardiographic manifestations of complications of radiation therapy, Echocardiography 26 (2009) 724-728.
62. Heidenreich P.A., Kapoor J.R., Radiation induced heart disease: systemic disorders in heart disease, Heart 95 (2009) 252-258.
63. Heidenreich P.A., Hancock S.L., Lee B.K., Mariscal C.S., Schnittger I., Asymptomatic cardiac disease following mediastinal irradiation, J Am Coll Cardiol 42 (2003) 743-749.
64. Tomlinson D., Mermel L.A., Ethier M.C., MatlowA., Gillmeister B., Sung L., Defining bloodstream infections related to central venous catheters in patients with cancer: a systematic review, Clin Infect Dis 53 (2011) 697-710.
65. Baumgartner H., Hung J., Bermejo J., Chambers J.B., Evangelista A., Griffin B.P. et al., Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice, J Am Soc Echocardiogr 22 (2009) 1-23. quiz 101-2.
66. Lancellotti P., Tribouilloy C., Hagendorff A., Popescu B.A., Edvardsen T., Pierard L.A. et al., Recommendations for the echocardiographic assessment of native valvular regurgitation: an executivesummary from the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging 14 (2013) 611-644.
67. Cosyns B., Garbi M., Separovic J., Pasquet A., Lancellotti P., Education Committee of the European Association of Cardiovascular Imaging Association (EACVI). Update of the Echocardiography Core Syllabus of the European Association of Cardiovascular Imaging (EACVI), Eur Heart J Cardiovasc Imaging 14 (2013) 837-839.
68. ZoghbiW.A., Enriquez-Sarano M., Foster E., Grayburn P.A., Kraft C.D., Levine R.A. et al., Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography, J Am Soc Echocardiogr 16 (2003) 777-802.
69. Mugge A., DanielW.G., Frank G., Lichtlen P.R., Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach, J Am Coll Cardiol 14 (1989) 631-638.
70. Klein A.L., Abbara S., Agler D.A., Appleton C.P., Asher C.R., Hoit B. et al., American society of echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the society for cardiovascular magnetic resonance and society of cardiovascular computed tomography, J Am Soc Echocardiogr 26 (2013) 965-1012. e15.
71. Bonow R.O., Carabello B.A., Chatterjee K., de Leon A.C. Jr., Faxon D.P., Freed M.D. et al., 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, J Am Coll Cardiol 52 (2008) e1-e142.
72. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC)European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A., Alfieri O., Andreotti F., Antunes M.J. et al., Guidelines on the management of valvular heart disease (version 2012), Eur Heart J 33 (2012) 2451-2496.
73. Morton D.L., Glancy D.L., JosephW.L., Adkins P.C., Management of patients with radiation-induced pericarditis with effusion: a note on the development of aortic regurgitation in two of them, Chest 64 (1973) 291-297.
74. Gaya A.M., Ashford R.F., Cardiac complications of radiation therapy, Clin Oncol (R Coll Radiol) 17 (2005) 153-159.
75. Krupicka J., Markova J., Pohlreich D., Kozak T., Linkova H., Diehl V. et al., Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group, Leuk Lymphoma 43 (2002) 2325-2329.
76. Tohda S., Kobayashi H., Suzuki T., Koyama T., Kamiyama T., Nakamura Y. et al., Acute pericarditis caused by daunorubicin in acute myelocytic leukemia, Rinsho Ketsueki 29 (1988) 874-878.
77. Casey D.J., Kim A.Y., Olszewski A.J., Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma, Am J Hematol 87 (2012) 521-524.
78. Dazzi H., Kaufmann K., Follath F., Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996, Ann Oncol 12 (2001) 963-966.
79. Katayama M., Imai Y., Hashimoto H., Kurata M., Nagai K., Tamita K. et al., Fulminant fatal cardiotoxicity following cyclophosphamide therapy, J Cardiol 54 (2009) 330-334.
80. Santos G.W., Sensenbrenner L.L., Burke P.J., Colvin M., Owens A.H. Jr., BiasW.B. et al., Marrow transplanation in man following cyclophosphamide, Transplant Proc 3 (1971) 400-404.
81. Gottdiener J.S., Appelbaum F.R., Ferrans V.J., Deisseroth A., Ziegler J., Cardiotoxicity associated with high-dose cyclophosphamide therapy, Arch Intern Med 141 (1981) 758-763.
82. Goldberg M.A., Antin J.H., Guinan E.C., Rappeport J.M., Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor, Blood 68 (1986) 1114-1118.
83. Yamamoto R., Kanda Y., Matsuyama T., Oshima K., NannyaY., Suguro M. et al., Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure, Bone Marrow Transplant 26 (2000) 685-688.
84. Braverman A.C., Antin J.H., Plappert M.T., Cook E.F., Lee R.T., Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens, J Clin Oncol 9 (1991) 1215-1223.
85. Gahler A., Hitz F., Hess U., Cerny T., Acute pericarditis and pleural effusion complicating cytarabine chemotherapy, Onkologie 26 (2003) 348-350.
86. Reykdal S., Sham R., Kouides P., Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy, Leuk Res 19 (1995) 141-144.
87. Yamada T., Tsurumi H., Hara T., Sawada M., Oyama M., Moriwaki H., Cytarabine-induced pericarditis, Rinsho Ketsueki 39 (1998) 1115-1120.
88. Hermans C., Straetmans N., Michaux J.L., Ferrant A., Pericarditis induced by highdose cytosine arabinoside chemotherapy, Ann Hematol 75 (1997) 55-57.
89. Vaickus L., Letendre L., Pericarditis induced by high-dose cytarabine therapy, Arch Intern Med 144 (1984) 1868-1869.
90. Barton J.C., Jones S.C., LamberthW.C., Reymann M.T., Scott V.C., Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia, Am J Hematol 71 (2002) 139-140.
91. Breccia M., D'Elia G.M., D'Andrea M., Latagliata R., Alimena G., Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib, Eur J Haematol 74 (2005) 89-90.
92. Breccia M., Alimena G., Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development, Expert Opin Drug Saf 9 (2010) 713-721.
93. Krauth M.T., Herndlhofer S., Schmook M.T., Mitterbauer-Hohendanner G., Schlogl E., Valent P., Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily, Haematologica 96 (2011) 163-166.
94. Rauw J., Ahmed S., Petrella T., Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma, Med Oncol 29 (2012) 1304-1307.
95. Cervera Miguel J.I., Vallalta M., Iranzo E., Navarro Ibanez V., Pericardial effusion associated with interferon therapy, Med Clin (Barc) 122 (2004) 636-637.
96. Velasco J., Orinuela I., Sanjuan A.Z., Ortiz de Zarate Z., Pericardial effusion associated to interferon in an immunocompetent patient, Enferm Infecc Microbiol Clin 28 (2010) 749-750.
97. Wisniewski B., Denis J., Fischer D., Labayle D., Pericarditis secondary to interferon alpha in chronic hepatitis C, Gastroenterol Clin Biol 28 (2004) 315-316.
98. Popescu C., Arama V., Gliga S., Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis-case report, BMC Gastroenterol 11 (2011) 30-230. X-11-30.
99. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A. et al., All-trans-retinoic acid in acute promyelocytic leukemia, N Engl J Med 337 (1997) 1021-1028.
100. Frankel S.R., Eardley A., Lauwers G.,Weiss M.,Warrell R.P. Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia, Ann Intern Med 117 (1992) 292-296.
101. TerpstraW., de Maat C.E., Pericardial fibrosis following busulfan treatment, Neth J Med 35 (1989) 249-252.
102. Forbat L.N., Hancock B.W., Gershlick A.H., Methotrexate-induced pericarditis and pericardial effusion; first reported case, Postgrad Med J 71 (1995) 244-245.
103. Savoia F., Gaddoni G., Casadio C., Patrizi A., Spadola G., Bassi P. et al., A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy, Dermatol Online J 16 (2010) 13.
104. Mohyuddin T., Elyan M., Kushner I., Pericarditis: a rare complication of methotrexate therapy, Clin Rheumatol 26 (2007) 2157-2158.
105. Palungwachira P., Palungwachira P., Laohathai P., Methotrexate induced pericarditis and pericardial effusion in psoriatic patient, J Med Assoc Thai 81 (1998) 141-145.
106. Huang S.Y., Chang C.S., Tang J.L., Tien H.F., Kuo T.L., Huang S.F. et al., Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia, Br J Haematol 103 (1998) 1092-1095.
107. Ueda K., Nagai S., Miyashita S.I., Kaise T., Ichikawa M., Kumano K. et al., Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome, Leuk Res 34 (2010) e25-e26.
108. Calik A.N., Celiker E., Velibey Y., Cagdas M., Guzelburc O., Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis, Am J Emerg Med 30 (2012) 257.e1-257.e3.
109. Vincenzi B., Santini D., Frezza A.M., Rocci L., Tonini G., Docetaxel induced pericardial effusion, J Exp Clin Cancer Res 26 (2007) 417-420.
110. Maisch B., Seferovic P.M., Ristic A.D., Erbel R., Rienmuller R., Adler Y. et al., Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology, Eur Heart J 25 (2004) 587-610.
111. Appleton C.P., Hatle L.K., Popp R.L., Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography, J Am Coll Cardiol 11 (1988) 1020-1030.
112. Pepi M., Muratori M., Echocardiography in the diagnosis and management of pericardial disease, J Cardiovasc Med 7 (2006) 533-544.
113. Wann S., Passen E., Echocardiography in pericardial disease, J Am Soc Echocardiogr 21 (2008) 7-13.
114. Applefeld M.M., Cole J.F., Pollock S.H., Sutton F.J., Slawson R.G., Singleton R.T. et al., The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's disease, Ann Intern Med 94 (1981) 338-341.
115. Kane G.C., Edie R.N., Mannion J.D., Delayed appearance of effusive-constrictive pericarditis after radiation for Hodgkin lymphoma, Ann Intern Med 124 (1996) 534-535.
116. Tulleken J.E., Kooiman C.G., van derWerf T.S., Zijlstra J.G., de Vries E.G., Constrictive pericarditis after high-dose chemotherapy, Lancet 350 (1997) 1601.
117. Oki T., Tabata T., Yamada H., Abe M., Onose Y.,Wakatsuki T. et al., Right and left ventricular wall motion velocities as diagnostic indicators of constrictive pericarditis, Am J Cardiol 81 (1998) 465-470.
118. Sengupta P.P., Mohan J.C., Mehta V., Arora R., Pandian N.G., Khandheria B.K., Accuracy and pitfalls of early diastolic motion of the mitral annulus for diagnosing constrictive pericarditis by tissue Doppler imaging, Am J Cardiol 93 (2004) 886-890.
119. SohnD.W., KimY.J., Kim H.S., Kim K.B., ParkY.B., Choi Y.S., Unique features of early diastolic mitral annulus velocity in constrictive pericarditis, J AmSoc Echocardiogr 17 (2004) 222-226.
120. Badano L.P., Boccalini F., Muraru D., Bianco L.D., Peluso D., Bellu R. et al., Current clinical applications of transthoracic three-dimensional echocardiography, J Cardiovasc Ultrasound 20 (2012) 1-22.
121. Armstrong G.T., Plana J.C., Zhang N., Srivastava D., Green D.M., Ness K.K. et al., Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging, J Clin Oncol 30 (2012) 2876-2884.
122. Jenkins C., Moir S., Chan J., Rakhit D., Haluska B., Marwick T.H., Left ventricular volumemeasurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging, Eur Heart J 30 (2009) 98-106.
123. King D.L., HarrisonM.R., King D.L. Jr., Gopal A.S., Kwan O.L., DeMaria A.N., Ultrasound beam orientation during standard two-dimensional imaging: assessment by three-dimensional echocardiography, J Am Soc Echocardiogr 5 (1992) 569-576.
124. Cannesson M., Tanabe M., Suffoletto M.S., McNamara D.M., Madan S., Lacomis J.M. et al., A novel two-dimensional echocardiographic image analysis system using artificial intelligence-learned pattern recognition for rapid automated ejection fraction, J Am Coll Cardiol 49 (2007) 217-226.
125. Muraru D., Badano L.P., Piccoli G., Gianfagna P., Del Mestre L., Ermacora D. et al., Validation of a novel automated border-detection algorithm for rapid and accurate quantitation of left ventricular volumes based on three-dimensional echocardiography, Eur J Echocardiogr 11 (2010) 359-368.
126. Mor-Avi V., Lang R.M., Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy?, J Am Coll Cardiol 61 (2013) 85-87.
127. TsangW., Kenny C., Adhya S., Kapetanakis S.,Weinert L., Lang R.M. et al., Interinstitutional measurements of left ventricular volumes, speckle-tracking strain, and dyssynchrony using three-dimensional echocardiography, J Am Soc Echocardiogr 26 (2013) 1253-1257.
128. Yu E.H., Sloggett C.E., Iwanochko R.M., Rakowski H., Siu S.C., Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients, J Am Soc Echocardiogr 13 (2000) 216-224.
129. Mulvagh S.L., Rakowski H., Vannan M.A., Abdelmoneim S.S., Becher H., Bierig S.M. et al., American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography, J Am Soc Echocardiogr 21 (2008) 1179-1201. quiz 1281.
130. Senior R., Becher H., Monaghan M., Agati L., Zamorano J., Vanoverschelde J.L. et al., Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography, Eur J Echocardiogr 10 (2009) 194-212.
131. Douglas P.S., Carr J.J., Cerqueira M.D., Cummings J.E., Gerber T.C., Mukherjee D. et al., Developing an action plan for patient radiation safety in adult cardiovascular medicine: proceedings from the Duke University Clinical Research Institute/ American College of Cardiology Foundation/American Heart Association Think Tank held on February 28, 2011, J Am Coll Cardiol 59 (2012) 1833-1847.
132. Yeh E.T.H., Bickford C.L., Cardiovascular Complications of Cancer Therapy: Incidence, Pathogenesis, Diagnosis, and Management, J Am Coll Cardiol 53 (2009) 2231-2247.
133. Jarfelt M., Kujacic V., Holmgren D., Bjarnason R., Lannering B., Exercise echocardiography reveals sub-clinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia, Pediatr Blood Cancer 49 (2007) 835-840.
134. DeWolf D., Suys B., Maurus R., Benoit Y., Verhaaren H., Matthijs D. et al., Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors, Pediatr Res 39 (1996) 504-512.
135. DeWolf D., Suys B., Verhaaren H., Matthys D., TaeymansY., Low-dose dobutamine stress echocardiography in children and young adults, Am J Cardiol 81 (1998) 895-901.
136. Cottin Y., L'huillier I., Casasnovas O., Geoffroy C., Caillot D., Zeller M. et al., Dobutamine stress echocardiography identifies anthracycline cardiotoxicity, Eur J Echocardiogr 1 (2000) 180-183.
137. Lanzarini L., Bossi G., Laudisa M.L., Klersy C., Arico M., Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-termchildhood cancer survivors exposed to anthracyclines, Am Heart J 140 (2000) 315-323.
138. Elbl L., Hrstkova H., ChaloupkaV., Novotny J., Michalek J., The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography, Neoplasma 50 (2003) 191-197.
139. HamadaH., Ohkubo T.,Maeda M.,Ogawa S., Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracyclinetreated survivors of childhood cancer, Pediatr Int 48 (2006) 313-320.
140. Civelli M., Cardinale D., Martinoni A., Lamantia G., Colombo N., Colombo A. et al., Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity, Int J Cardiol 111 (2006) 120-126.
141. Grosu A., Bombardini T., Senni M., Duino V., Gori M., Picano E., End-systolic pressure/ volume relationship during dobutamine stress echo: a prognostically useful non-invasive index of left ventricular contractility, Eur Heart J 26 (2005) 2404-2412.
142. Tan-Chiu E., Yothers G., Romond E., Geyer C.E. Jr., Ewer M., Keefe D. et al., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapyinnode-positive,humanepidermal growthfactor receptor 2-overexpressing breast cancer: NSABP B-31, J Clin Oncol 23 (2005) 7811-7819.
143. Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G. et al., Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy, J Am Coll Cardiol 55 (2010) 213-220.
144. Stoddard M.F., Seeger J., Liddell N.E., Hadley T.J., Sullivan D.M., Kupersmith J., Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans, J Am Coll Cardiol 20 (1992) 62-69.
145. Dorup I., Levitt G., Sullivan I., Sorensen K., Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function, Heart 90 (2004) 1214-1216.
146. EidemB.W., Sapp B.G., Suarez C.R., Cetta F., Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children, Am J Cardiol 87 (2001) 1120-1122. A9.
147. Ishii M., Tsutsumi T., HimenoW., Eto G., Furui J., Hashino K. et al., Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy, Am J Cardiol 86 (2000) 1279-1281. A9.
148. Rohde L.E., Baldi A.,Weber C., Geib G., Mazzotti N.G., Fiorentini M. et al., Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity, Int J Cardiovasc Imaging 23 (2007) 185-191.
149. Pellicori P., Calicchia A., Lococo F., Cimino G., Torromeo C., Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol, Congest Heart Fail 18 (2012) 217-221.
150. Ho E., Brown A., Barrett P., Morgan R.B., King G., Kennedy M.J. et al., Subclinical anthracycline-and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study, Heart 96 (2010) 701-707.
151. Nagy A.C., Tolnay E., Nagykalnai T., Forster T., Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI, Neoplasma 53 (2006) 511-517.
152. Nagy A.C., Cserep Z., Tolnay E., Nagykalnai T., Forster T., Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study, Pathol Oncol Res 14 (2008) 69-77.
153. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., CohenV. et al., Early detection and prediction of cardiotoxicity in chemotherapy-treated patients, Am J Cardiol 107 (2011) 1375-1380.
154. Ganame J., Claus P., Uyttebroeck A., Renard M., D'hooge J., Bijnens B. et al., Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients, J Am Soc Echocardiogr 20 (2007) 1351-1358.
155. Negishi K., Negishi T., Hare J.L., Haluska B.A., Plana J.C., Marwick T.H., Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity, J Am Soc Echocardiogr 26 (2013) 493-498.
156. Fallah-Rad N.,Walker J.R.,Wassef A., Lytwyn M., Bohonis S., FangT. et al., The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy, J Am Coll Cardiol 57 (2011) 2263-2270.
157. Thavendiranathan P., Poulin F., Lim K.D., Plana J.C.,Woo A., Marwick T.H., Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review, J Am Coll Cardiol 63 (2014) 2751-2768.
158. Jurcut R., Wildiers H., Ganame J., D'hooge J., De Backer J., Denys H. et al., Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer, J Am Soc Echocardiogr 21 (2008) 1283-1289.
159. Poterucha J.T., Kutty S., Lindquist R.K., Li L., Eidem B.W., Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction, J Am Soc Echocardiogr 25 (2012) 733-740.
160. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C. et al., Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab, Circ Cardiovasc Imaging 5 (2012) 596-603.
161. Stoodley P.W., Richards D.A., Hui R., Boyd A., Harnett P.R., Meikle S.R. et al., Twodimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy, Eur J Echocardiogr 12 (2011) 945-952.
162. Hare J.L., Brown J.K., Leano R., Jenkins C., Woodward N., Marwick T.H., Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab, Am Heart J 158 (2009) 294-301.
163. Cheung Y.F., HongW.J., Chan G.C.,Wong S.J., Ha S.Y., Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy, Heart 96 (2010) 1137-1141.
164. Tsai H.R., Gjesdal O.,Wethal T., Haugaa K.H., Fossa A., Fossa S.D. et al., Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-termsurvivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy, Am J Cardiol 107 (2011) 472-477.
165. Kocabay G., Muraru D., Peluso D., Cucchini U., Mihaila S., Padayattil-Jose S. et al., Normal left 1 ventricular mechanics by two-dimensional speckle tracking echocardiography. Reference values in healthy adults, Rev Esp Cardiol, 2014.
166. Takigiku K., Takeuchi M., Izumi C., Yuda S., Sakata K., Ohte N. et al., Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study, Circ J 76 (2012) 2623-2632.
167. KuznetsovaT., Herbots L., RichartT., D'hooge J., Thijs L., Fagard R.H. et al., Left ventricular strain and strain rate in a general population, Eur Heart J 29 (2008) 2014-2023.
168. Cheng S., Larson M.G., McCabe E.L., Osypiuk E., Lehman B.T., Stanchev P. et al., Reproducibility of Speckle-Tracking-Based Strain Measures of Left Ventricular Function in a Community-Based Study, J Am Soc Echocardiogr 26 (2013) 1258-1266.e2.
169. Risum N., Ali S., Olsen N.T., Jons C., Khouri M.G., Lauridsen T.K. et al., Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults, J Am Soc Echocardiogr 25 (2012) 1195-1203.
170. A Unique Collaboration to Advance Strain Imaging, Journal of the American Society of Echocardiography 26 (2013) A21-A22.
171. Cardinale D., Sandri M.T., Role of biomarkers in chemotherapy-induced cardiotoxicity, Prog Cardiovasc Dis 53 (2010) 121-129.
172. Reichlin T., HochholzerW., Bassetti S., Steuer S., Stelzig C., Hartwiger S. et al., Early diagnosis of myocardial infarction with sensitive cardiac troponin assays, N Engl J Med 361 (2009) 858-867.
173. Wright R.S., Anderson J.L., Adams C.D., Bridges C.R., Casey D.E. Jr., Ettinger S.M. et al., 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-STElevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons, J Am Coll Cardiol 57 (2011) e215-367.
174. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G. et al., Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy, Circulation 109 (2004) 2749-2754.
175. AunerH.W., Tinchon C., LinkeschW., Tiran A., Quehenberger F., Link H. et al., Prolonged monitoring of troponinTfor the detectionof anthracycline cardiotoxicity in adults with hematological malignancies, Ann Hematol 82 (2003) 218-222.
176. Specchia G., Buquicchio C., Pansini N., Di Serio F., LisoV., Pastore D. et al., Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines, J Lab Clin Med 145 (2005) 212-220.
177. Kilickap S., Barista I., Akgul E., Aytemir K., Aksoyek S., Aksoy S. et al., cTnT can be a useful marker for early detection of anthracycline cardiotoxicity, Ann Oncol 16 (2005) 798-804.
178. Cardinale D., Colombo A., Torrisi R., Sandri M.T., Civelli M., Salvatici M. et al., Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation, J Clin Oncol 28 (2010) 3910-3916.
179. Morris P.G., Chen C., Steingart R., Fleisher M., Lin N., Moy B. et al., Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib, Clin Cancer Res 17 (2011) 3490-3499.
180. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C. et al., Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol 26 (2008) 5204-5212.
181. Ederhy S., Massard C., Dufaitre G., Balheda R., Meuleman C., Rocca C.G. et al., Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials, Invest New Drugs 30 (2012) 611-615.
182. Lenihan D.J., Massey M.R., Baysinger K.B., Adorno C.L.,Warneke C.L., Steinert D. et al., Superior Detection of Cardiotoxicity during Chemotherapy Using Biomarkers, J Card Fail 13 (2007) S151.
183. Romano S., Fratini S., Ricevuto E., Procaccini V., Stifano G., Mancini M. et al., Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients, Br J Cancer 105 (2011) 1663-1668.
184. Dodos F., Halbsguth T., Erdmann E., Hoppe U.C., Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults, Clin Res Cardiol 97 (2008) 318-326.
185. Knobloch K., Tepe J., Lichtinghagen R., Luck H.J., Vogt P.M., Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide, Clin Med 7 (2007) 88-89. author reply 89.
186. Knobloch K., Tepe J., Rossner D., Lichtinghagen R., Luck H.J., Busch K.H. et al., Combined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy, Int J Cardiol 128 (2008) 316-325.
187. Nousiainen T., Jantunen E., Vanninen E., Remes J., Vuolteenaho O., Hartikainen J., Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma, Eur J Haematol 62 (1999) 135-141.
188. Fish M, Lenihan DJ. Effectiveness of using biomarkers to detect and identify cardiotoxicity and describe treatment (PREDICT). 2013;(Accessed 2014 Mar 11) http ://clinicaltrials.gov/ct2/show/NCT01311843.
189. Kalam K., Marwick T.H., Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis, Eur J Cancer 49 (2013) 2900-2909.
190. Lipshultz S.E., Rifai N., Dalton V.M., Levy D.E., Silverman L.B., Lipsitz S.R. et al., The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia, N Engl J Med 351 (2004) 145-153.
191. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C., Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database Syst Rev (2011) CD003917.
192. Seicean S., Seicean A., Plana J.C., Budd G.T., Marwick T.H., Effect of statin therapyon the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study, J Am Coll Cardiol 60 (2012) 2384-2390.
193. Acar Z., Kale A., Turgut M., Demircan S., Durna K., Demir S. et al., Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy, J Am Coll Cardiol 58 (2011) 988-989.
194. Silber J.H., Cnaan A., Clark B.J., Paridon S.M., Chin A.J., Rychik J. et al., Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines, J Clin Oncol 22 (2004) 820-828.
195. Blaes A.H., Gaillard P., Peterson B.A., Yee D., Virnig B., Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy, Breast Cancer Res Treat 122 (2010) 585-590.
196. Seicean S., Seicean A., Alan N., Plana J.C., Budd G.T., Marwick T.H., Cardioprotective Effect of Beta-Adrenoceptor Blockade in Breast Cancer Patients Undergoing Chemotherapy: A Follow-Up Study of Heart Failure, Circ Heart Fail 6 (2013) 420-426.
197. Kalay N., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan A. et al., Protective effects of carvedilol against anthracycline-induced cardiomyopathy, J Am Coll Cardiol 48 (2006) 2258-2262.
198. Nakamae H., Tsumura K.,TeradaY., NakaneT., Nakamae M., Ohta K. et al., Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, Cancer 104 (2005) 2492-2498.
199. Cadeddu C., Piras A.,Mantovani G., Deidda M., Dessi M., Madeddu C. et al., Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment, Am Heart J 160 (2010) 487.e1-487.e7.
200. NegishiT., Negishi K., Agler D., Plana J.C., Haluska B., MarwickT., Cardio-protective effect of beta-blockade during chemotherapy for breat cancer, J Am Coll Cardiol 59 (2012) E1248.
201. Powe D.G., Entschladen F., Targeted therapies: Using beta-blockers to inhibit breast cancer progression, Nat Rev Clin Oncol 8 (2011) 511-512.
202. Gottdiener J.S., Mathisen D.J., Borer J.S., Bonow R.O., Myers C.E., Barr L.H. et al., Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography, Ann Intern Med 94 (1981) 430-435.
203. ChoiB.W., Berger H.J., Schwartz P.E., Alexander J.,Wackers F.J., Gottschalk A. et al., Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance, Am Heart J 106 (1983) 638-643.
204. Palmeri S.T., Bonow R.O., Myers C.E., Seipp C., Jenkins J., Green M.V. et al., Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography, Am J Cardiol 58 (1986) 607-613.
205. Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H., Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer, J Clin Oncol 25 (2007) 3808-3815.
206. Bellenger N.G., Burgess M.I., Ray S.G., Lahiri A., Coats A.J., Cleland J.G. et al., Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?, Eur Heart J 21 (2000) 1387-1396.
207. Naik M.M., Diamond G.A., Pai T., Soffer A., Siegel R.J., Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography, J Am Coll Cardiol 25 (1995) 937-942.
208. Mogelvang J., Stokholm K.H., Saunamaki K., Reimer A., Stubgaard M., Thomsen C. et al., Assessment of left ventricular volumes by magnetic resonance in comparison with radionuclide angiography, contrast angiography and echocardiography, Eur Heart J 13 (1992) 1677-1683.
209. Jiji R.S., Kramer C.M., Salerno M., Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs, J Nucl Cardiol 19 (2012) 377-388.
210. van Royen N., Jaffe C.C., Krumholz H.M., Johnson K.M., Lynch P.J., Natale D. et al., Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions, Am J Cardiol 77 (1996) 843-850.
211. Abbasi S.A., Ertel A., Shah R.V., Dandekar V., Chung J., Bhat G. et al., Impact of cardiovascular magnetic resonance on management and clinical decisionmaking in heart failure patients, J Cardiovasc Magn Reson 15 (2013) 89-429. X-15-89.
212. Greenwood J.P., Maredia N., Younger J.F., Brown J.M., Nixon J., Everett C.C. et al., Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial, Lancet 379 (2012) 453-460.
213. Klein C., Nekolla S.G., Bengel F.M., Momose M., Sammer A., Haas F. et al., Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography, Circulation 105 (2002) 162-167.
214. Neilan T.G., Coelho-Filho O.R., Pena-Herrera D., Shah R.V., Jerosch-Herold M., Francis S.A. et al., Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines, Am J Cardiol 110 (2012) 1679-1686.
215. Smith G., Kotwinski P., Carpenter J.P.,Hugh M., Pennell D., Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity, J Cardiovasc Magn Reson 11 (2009) P18.
216. Pennell D.J., Sechtem U.P., Higgins C.B., Manning W.J., Pohost G.M., Rademakers F.E. et al., Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report, J Cardiovasc Magn Reson 6 (2004) 727-765.
217. Kawel N., Turkbey E.B., Carr J.J., Eng J., Gomes A.S., HundleyW.G. et al., Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis, Circ Cardiovasc Imaging 5 (2012) 500-508.
218. The clinical role of magnetic resonance in cardiovascular disease. Task Force of the European Society of Cardiology, in collaboration with the Association of European Paediatric Cardiologists, Eur Heart J 19 (1998) 19-39.
219. Bellenger N.G., Davies L.C., Francis J.M., Coats A.J., Pennell D.J., Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance, J Cardiovasc Magn Reson 2 (2000) 271-278.
220. Grothues F., Smith G.C., Moon J.C., Bellenger N.G., Collins P., Klein H.U. et al., Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy, Am J Cardiol 90 (2002) 29-34.
221. Armstrong A.C., Gidding S., Gjesdal O., Wu C., Bluemke D.A., Lima J.A., LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice, JACC Cardiovasc Imaging 5 (2012) 837-848.
222. Vogel-Claussen J., Finn J.P., Gomes A.S., Hundley G.W., Jerosch-Herold M., Pearson G. et al., Left ventricular papillary musclemass: relationship to left ventricular mass and volumes by magnetic resonance imaging, J Comput Assist Tomogr 30 (2006) 426-432.
223. Alfakih K., Bloomer T., Bainbridge S., Bainbridge G., Ridgway J., Williams G. et al., A comparison of left ventricular mass between two-dimensional echocardiography, using fundamental and tissue harmonic imaging, and cardiac MRI in patients with hypertension, Eur J Radiol 52 (2004) 103-109.
224. Missouris C.G., Forbat S.M., Singer D.R., Markandu N.D., Underwood R., MacGregor G.A., Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension, J Hypertens 14 (1996) 1005-1010.
225. Goldman M., Matthews R., Meng H., Bilfinger T., Kort S., Evaluation of cardiac involvement with mediastinal lymphoma: the role of innovative integrated cardiovascular imaging, Echocardiography 29 (2012) E189-E192.
226. Kim R.J., Wu E., Rafael A., Chen E.L., Parker M.A., Simonetti O. et al., The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction, N Engl J Med 343 (2000) 1445-1453.
227. Perez-Rodriguez J., Lai S., Ehst B.D., Fine D.M., Bluemke D.A., Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases, Radiology 250 (2009) 371-377.
228. Iles L., Pfluger H., Phrommintikul A., Cherayath J., Aksit P., Gupta S.N. et al., Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping, J Am Coll Cardiol 52 (2008) 1574-1580.
229. Ugander M., Oki A.J., Hsu L.Y., Kellman P., Greiser A., Aletras A.H. et al., Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology, Eur Heart J 33 (2012) 1268-1278.
230. Tham E., Chow K., Spavor M., Pagano J.J., Haykowsky M., Thompson R.J., Degree of diffuse fibrosis measured by MRI correlates with LV remodelling in childhood cancer survivors after anthracycline chemotherapy, J Cardiovasc Magn Reson 13 (2011) P276.
231. Neilan T.G., Coelho-Filho O.R., Shah R.V., Feng J.H., Pena-Herrera D., Mandry D. et al., Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy, Am J Cardiol 111 (2013) 717-722.
232. Korinek J., Kjaergaard J., Sengupta P.P., Yoshifuku S., McMahon E.M., Cha S.S. et al., High spatial resolution speckle tracking improves accuracy of 2-dimensional strain measurements: an update on a new method in functional echocardiography, J Am Soc Echocardiogr 20 (2007) 165-170.
233. Drafts B.C., Twomley K.M., D'Agostino R. Jr., Lawrence J., Avis N., Ellis L.R. et al., Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of sub-clinical cardiovascular disease, JACC Cardiovasc Imaging 6 (2013) 877-885.
234. Mornos C., Petrescu L., Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist, Can J Physiol Pharmacol 91 (2013) 601-607.
235. Baratta S., Damiano M., Marchese M., Trucco J., Rizzo M., Bernok F. et al., Serum Markers, Conventional Doppler Echocardiography and Two-dimensional Systolic Strain in the Diagnosis of Chemotherapy-Induced Myocardial Toxicity, Rev Argent Cardiol 81 (2013) 151-158.
236. Mavinkurve-Groothuis A.M., Marcus K.A., Pourier M., Loonen J., Feuth T., Hoogerbrugge P.M. et al., Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study, Eur Heart J Cardiovasc Imaging 14 (2013) 562-569.
237. Stanton T., Leano R., Marwick T.H., Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring, Circ Cardiovasc Imaging 2 (2009) 356-364.
238. Cho G.Y., Marwick T.H., Kim H.S., Kim M.K., Hong K.S., Oh D.J., Global 2-dimensional strain as a new prognosticator in patients with heart failure, J Am Coll Cardiol 54 (2009) 618-624.